

REMARKS/ARGUMENTS

The Office Action of March 3, 2004 has been carefully reviewed and these remarks are responsive thereto. Reconsideration and allowance of the instant application are respectfully requested.

Independent claim 1 and dependent claims 2, 4-7 and 18-23 are pending. Claims 1, 2, 4, 20-23 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Rise (U.S. Pat. No. 5,643,203) in view of Seckel (U.S. Patent No. 5,584,885). Claims 5 and 6 were rejected under U.S.C. § 103(a) in over Rise in view of Seckel and in further view of Hadden (U.S. Pat. No. 5,632,983) and Masters (U.S. Application No. 2003/0007991). Claims 7, 18, and 19 were rejected over Rise in view of Seckel and in further Medenica et al. (U.S. Pat. No. 5,738,129). The applicant respectfully traverses the rejections of claims 1, 2, 4-7 and 18-23 and submits the following remarks.

Use of Masters as a Prior Art Reference

The Office Action states that Masters claims priority to application 09/160,424 which has a filing date of September 25, 1998. While not admitting that a filing date of September 25, 1998 would qualify a reference as prior art, the Applicant respectfully submits that Masters is a continuation-in-part from the 09/160,424 application. The Office Action did not suggest that the application, S/N 09/160,424, would support a 35 U.S.C. § 103(a) rejection. Thus, as the full subject matter of the Masters reference can only claim priority to the August 3, 2000 filing date, it appears that the Masters reference cannot fairly be considered prior art for the current application under 35 U.S.C. § 103(a). Therefore, withdrawal of any rejection based on the Masters reference is respectfully requested.

Rejection Under 35 U.S.C. § 103(a) – Rise in View of Seckel

Claims 1, 2, 4, 20-23 were rejected under § 103(a) over Rise in view of Seckel. Seckel is directed towards the growth of biological tissue. Seckel states:

The present invention provides a regeneration chamber for promoting and controlling the growth of biological tissues.

(Seckel, Col. 3, Ln. 56-57). Thus, Seckel teaches the use of a chamber for controlling the growth of biological tissue. The Applicant has reviewed Seckel and has been unable to find any reference to any embodiment that does not use a chamber. If the Examiner disagrees, the Applicant respectfully requests that the specific location in the Seckel reference that discloses the use of catheter be reference pursuant to MPEP 706.02(j)(A).

Nor is the Applicant aware of any teaching in the Seckel reference that suggests that Seckel would be suitable for use with a catheter. In contrast to the teaching of Seckel, claim 1 recites "implantable infusion device for delivering a medicament composition to a target site in the living body through a catheter" with "the medicament composition including living cells." The Applicant respectfully asserts that, unlike claim 1, Seckel teaches away from the use of a catheter because a chamber with an inlet and outlet port is always used:

The exit flow path through Output Port 16 further provides a pressure relief path which allows agents and other substances in Chamber 12 to flow from Chamber 12 through Output Port 16 when pressure in Chamber 12 increases. The pressure in Chamber 12 may increase, for example, when new agents are injected through the Input Port 14 or because of the accumulation of byproducts from the regeneration process. Output Port 16 thereby prevents the occurrence of pressures within Chamber 12 that would be detrimental to the healing and regeneration process or possibly even force Proximal End 18 or Distal End 20 of Nerve 22 out of the Chamber 12.

(Seckel, Col. 6, Ln. 3-14). Therefore, the use of a catheter would be contrary to the invention disclosed in Seckel. Moreover, using the present application as a road map to combine Rise and Seckel to achieve the present invention is improper hindsight reconstruction.

Thus, the Applicant respectfully submits that nothing in Seckel suggests the combination of Seckel with Rise nor is there any indication that such a combination would be successful. See MPEP 706.02(j) ("To establish a *prima facie* case of obviousness, three basic criterion must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success."). As

Appln. No.: 10/005,789
Amendment dated April 27, 2004
Reply to Final Office Action mailed March 3, 2004

Rise cannot properly be combined with Seckel, the combination of Rise and Seckel cannot make obvious claim 1. Moreover, Hadden and Medenica do not overcome the deficiencies in the teachings of Seckel and Rise. Therefore, the Applicant respectfully requests withdrawal of this ground of rejection.

Claims 2, 4-7, and 18-23 depend from claim 1 and are nonobvious for all the above reasons and because of the additional limitations recited therein. Thus, the additional rejections of the dependent claims are respectfully deemed moot in light of the traverse of the rejection of claim 1.

CONCLUSION

It is believed that no fee is required for this submission. If any fees are required or if an overpayment is made, the Commissioner is authorized to debit or credit our Deposit Account No. 19-0733, accordingly.

All rejections and objections having been addressed, Applicant respectfully submits that the instant application is in condition for allowance, and respectfully solicits prompt notification of the same.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: April 27, 2004

By:



Scott A. Burow

Registration No. 42,373

Banner & Witcoff, LTD.
Ten South Wacker Drive
Chicago, Illinois 60606
Tel: (312) 463-5000
Fax: (312) 463-5001